These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 19509121)
1. The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture. Stevenson MD; Oakley JE; Lloyd Jones M; Brennan A; Compston JE; McCloskey EV; Selby PL Med Decis Making; 2009; 29(6):678-89. PubMed ID: 19509121 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128 [TBL] [Abstract][Full Text] [Related]
3. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective. Boonen S Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755 [TBL] [Abstract][Full Text] [Related]
4. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. Danese MD; Badamgarav E; Bauer DC J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313 [TBL] [Abstract][Full Text] [Related]
5. An integrated approach: bisphosphonate management for the treatment of osteoporosis. Owens G; Jackson R; Lewiecki EM Am J Manag Care; 2007 Dec; 13 Suppl 11():S290-308; quiz S309-12. PubMed ID: 18095779 [TBL] [Abstract][Full Text] [Related]
6. The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate. Stevenson MD; Jones ML Med Decis Making; 2011; 31(1):43-52. PubMed ID: 20375420 [TBL] [Abstract][Full Text] [Related]
7. Who will benefit from antiresorptive treatment (bisphosphonates)? Papapoulos SE Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):965-73. PubMed ID: 16301190 [TBL] [Abstract][Full Text] [Related]
8. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. McHorney CA; Schousboe JT; Cline RR; Weiss TW Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435 [TBL] [Abstract][Full Text] [Related]
9. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008. Siris ES; Pasquale MK; Wang Y; Watts NB J Bone Miner Res; 2011 Jan; 26(1):3-11. PubMed ID: 20662073 [TBL] [Abstract][Full Text] [Related]
10. [How to prevent early postmenopausal fracture risk? Proposition of a strategy]. Trémollieres F; Pouilles JM; Ribot C Gynecol Obstet Fertil; 2009 Jan; 37(1):50-6. PubMed ID: 19110461 [TBL] [Abstract][Full Text] [Related]
11. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland. Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511 [TBL] [Abstract][Full Text] [Related]
12. What is the optimal duration of bisphosphonate therapy? Ott SM Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
14. Is treatment of early postmenopausal women with bisphosphonates justified? Epstein S Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359 [TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis. Blair MM; Carson DS; Barrington R J Fam Pract; 2000 Sep; 49(9):839-48. PubMed ID: 11032210 [TBL] [Abstract][Full Text] [Related]
16. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis]. Soen S Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264 [TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial. Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789 [TBL] [Abstract][Full Text] [Related]
18. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture. Perreault S; Dragomir A; Blais L; Moride Y; Rossignol M; Ste-Marie LG; Fernandès JC Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):248-59. PubMed ID: 18213734 [TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498 [TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]